Tyrosine kinase inhibitorFDA-approvedFirst-line
Binimetinib
How it works
Blocks the MEK protein, a downstream target of the BRAF V600E mutation, allowing the cancer cells to die.
Cancer types
Melanoma— BRAF V600E mutation
Efficacy
In clinical trials, around 50% of patients achieved an objective response, with median progression-free survival of approximately 6.9 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Treatments for Advanced Triple Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing Binimetinib and Encorafenib for Metastatic Melanoma | Melanoma | phase-2 | — | Source → |
| Study of Encorafenib and Binimetinib in Metastatic Melanoma | Melanoma | phase-2 | — | Source → |
| Advanced Melanoma Treatment Trial Evaluates Combination of Three Study Medicines | Melanoma | phase-3 | — | Source → |
| Testing Binimetinib Plus Belinostat for Metastatic Uveal Melanoma | Melanoma | phase-2 | — | Source → |
| Testing Palbociclib and Binimetinib in RAS-Mutant Cancers | Pancreatic Cancer | phase-2 | — | Source → |
| Combining Metformin and Binimetinib May Help Fight Melanoma | Melanoma | lab-study | — | Source → |
| MEK Inhibitor Shows Modest Effectiveness in Advanced Melanoma | Melanoma | observational | The disease control rate was 60.0%. | Source → |
| Study of Encorafenib and Binimetinib for BRAF Mutant Melanoma with Brain Metastasis | Melanoma | phase-2 | Treatment with encorafenib plus binimetinib demonstrated a brain metastasis response rate of over 60%. | Source → |
| New Treatment Option for Lung Cancer Patients with V600E Mutation | Lung Cancer | phase-2 | Encorafenib plus binimetinib achieved the primary endpoint of objective response rate by independent review committee. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.